Article Text

PDF
Review
The use of biomarkers in neuroendocrine tumours
  1. Mohid Shakil Khan1,2,
  2. Martyn E Caplin2
  1. 1Neuroendocrine Tumour Unit, European Neuroendocrine Tumour Society Centre of Excellence, Centre for Gastroenterology, Royal Free Hospital, London, UK
  2. 2UCL Cancer Institute, London, UK
  1. Correspondence to Dr Mohid Shakil Khan, Neuroendocrine Tumour Unit, European Neuroendocrine Tumour Society Centre of Excellence, Centre for Gastroenterology, Royal Free Hospital, London NW3 2QG, UK; mohid.khan{at}nhs.net

Abstract

The incidence and prevalence of neuroendocrine tumours (NETs) arising from the gastrointestinal tract are increasing. At the time of diagnosis, histological grade, based on Ki-67 proliferation index on a tumour biopsy or specimen, offers prognostication but with often lengthy survival, this may not reflect current tumour biology later in the disease course. Biomarkers, including plasma chromogranin A, urinary 5-hydroxyindole acetic acid and pancreatic specific hormones (insulin, gastrin, vasoactive intestinal peptide), have a role in diagnosis but despite being incorporated into routine clinical practice, there is a lack of robust prospectively collected data investigating their prognostic and predictive value. Given the increasing number of treatment options available for NETs and prolonged survival, there is no agreement on the order of treatment for individual NET patients but the emergence of novel biomarkers and validation of existing ones, in addition to better understanding of the molecular biology, may help solve this clinical problem.

  • Cancer
  • Endocrine Tumours
  • Tumour Markers

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.